Bain Capital Ventures: Investment Portfolio & Startup News
Bain Capital Ventures
To add a bio or update investment portfolio click update information.
Investment Portfolio


OMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
OMass Therapeutics is a biotechnology company developing small molecule therapeutics against highly validated target ecosystems in endocrinology and immunology. OMass Therapeutics develops OMS1620 for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome and advances an SLC15A4 inhibitor for lupus and related diseases.


Navro raises £30m Series B led by Jump Capital to scale global payments platform for regulated industries
Navro provides a global payments platform that allows regulated organisations to manage cross-border collections and payouts through a single API, simplifying compliance-heavy international transactions.


Bain Capital Ventures leads £18m Series A in Northflank revolutionising app and database deployments
Northflank offers a cloud platform that lets developers deploy, scale and manage applications and databases across any cloud provider, replacing fragmented infrastructure tools with a unified self-service environment.
More venture news
- 17 Nov 2026

Isomorphic LabsIsomorphic Labs unlocks a £3.8bn Series C round led by Greenoaks and Sequoia Capital to design new medicines with AI
Series CLife Sciences - 11 Nov 2026

FractileFractile raises a £540m Series C from investors including Thrive and Founders Fund to build the chips that AI frontiers run on
Series CDeep Tech - 15 Oct 2026

OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences